<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01751646</url>
  </required_header>
  <id_info>
    <org_study_id>ATN 109 Version 2.0</org_study_id>
    <nct_id>NCT01751646</nct_id>
  </id_info>
  <brief_title>Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Effectiveness of Vitamin D3 50,000 IU Every 4 Weeks to Increase Bone Mineral Density and Decrease Tenofovir-Induced Hyperparathyroidism in Youth With HIV Infection Being Treated With Tenofovir-Containing Combination Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Westat</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Westat</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 48 week randomized double-blind, placebo-controlled prospective cohort study of
      adolescents and young adults with HIV infection in the ATN who are currently being treated
      with cART that includes TDF as one component of the regimen that includes at least three Food
      and Drug Administration (FDA)-approved ARVs for at least 180 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 48 week randomized double-blind, placebo-controlled prospective cohort study of
      adolescents and young adults with HIV infection in the ATN who are currently being treated
      with cART that includes TDF as one component of the regimen that includes at least three Food
      and Drug Administration (FDA)-approved ARVs for at least 180 days. Subjects must have at
      least one documented viral load that is below 200 copies/mL that is collected following
      initiation of TDF containing cART and greater than 90 days prior to randomization; no viral
      load above 200 copies/mL if measured within the 90 days prior to randomization; and an HIV
      viral load obtained at screening that is below 200 copies/mL.

      Treatment assignments will be balanced by subject sex at birth, age (&lt;20 years vs. &gt;=20
      years), and race (African American vs. other). Enrolled subjects will be randomized to
      receive vitamin D3 50000 IU or matching placebo, given orally every four weeks by DOT. In
      addition to the randomized study agent, all subjects will receive a MVI to be taken orally
      once daily. This &quot;standard&quot; MVI will contain ingredients not to exceed 600 IU of vitamin D3
      and 200 mg Ca.

      DXA measurement of whole-body BMC, and BMD at spine and hip, will be performed at baseline
      and study weeks 24 and 48. Blood and urine sampling to assess the Ca-PO4 axis,
      PTH-FGF23-vitamin D signaling, bone turnover, and renal glomerular and tubular function will
      occur at baseline and study weeks 12, 24, and 48 Blood samples to measure Gluc homeostasis
      will be drawn at baseline and week 48, and will be run by batch analysis.

      Safety, measured by SCa and SCr, will be monitored by subject's record review at study sites
      since these labs will generally be measured as a part of routine clinical care. The ATN109
      study will use the SCa and SCr values obtained within 10 weeks at the time of the visit
      beginning at the baseline visit. If these evaluations were not performed within the prior 10
      weeks they will be drawn at the time of the visit. Viral load and CD4 cell count results will
      be recorded for the ATN109 study at screening, baseline and study weeks 12, 24, 48, and
      Post-Week 48 provided the evaluations were done within the protocol specified timeframe. If
      the evaluations are not performed within the protocol specified timeframes they will be drawn
      at the time of the visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the percent change from baseline to week 48 in DXA-measured BMD at the spine for the randomized study groups</measure>
    <time_frame>48 weeks</time_frame>
    <description>To compare the percent change from baseline to week 48 in DXA-measured BMD at the spine for the randomized study groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare change from baseline to week 24 of BMC of whole body and BMD of spine, total hip, and femoral neck for the randomized study groups</measure>
    <time_frame>24 weeks</time_frame>
    <description>For BMC of whole body and BMD of spine, total hip, and femoral neck, compare change from baseline to week 24by randomized study group, with analyses using measured BMC/BMD and Z-scores;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare change from baseline to week 48 of BMC of whole body and BMD of spine, total hip, and femoral neck for the randomized study groups</measure>
    <time_frame>48 weeks</time_frame>
    <description>For BMC of whole body and BMD of spine, total hip, and femoral neck, compare change from baseline to week 48, by randomized study group, with analyses using measured BMC/BMD and Z-scores;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the time course of change from baseline to week 12 in SCa, UCa / UCr, SPO4, TRP, 25-OHD, 1,25-OHD, free 1,25-OHD index, PTH, FGF23, BAP, OC, and CTX</measure>
    <time_frame>12 weeks</time_frame>
    <description>To compare the time course of change from baseline to weeks 12 in SCa, UCa / UCr, SPO4, TRP, 25-OHD, 1,25-OHD, free 1,25-OHD index, PTH, FGF23, BAP, OC, and CTX;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the time course of change from baseline to week 24 in SCa, UCa / UCr, SPO4, TRP, 25-OHD, 1,25-OHD, free 1,25-OHD index, PTH, FGF23, BAP, OC, and CTX</measure>
    <time_frame>24 weeks</time_frame>
    <description>To compare the time course of change from baseline to week 24 in SCa, UCa / UCr, SPO4, TRP, 25-OHD, 1,25-OHD, free 1,25-OHD index, PTH, FGF23, BAP, OC, and CTX</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the time course of change from baseline to week 48 in SCa, UCa / UCr, SPO4, TRP, 25-OHD, 1,25-OHD, free 1,25-OHD index, PTH, FGF23, BAP, OC, and CTX</measure>
    <time_frame>48 weeks</time_frame>
    <description>To compare the time course of change from baseline to week 48 in SCa, UCa / UCr, SPO4, TRP, 25-OHD, 1,25-OHD, free 1,25-OHD index, PTH, FGF23, BAP, OC, and CTX;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in in SCr and estimated GFR from baseline to week 12.</measure>
    <time_frame>12 weeks</time_frame>
    <description>To assess renal glomerular safety by measuring change in SCr and estimated GFR from baseline to week 12 by randomized study group;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in in SCr and estimated GFR from baseline to week 24.</measure>
    <time_frame>24 weeks</time_frame>
    <description>To assess renal glomerular safety by measuring change in SCr and estimated GFR from baseline to week 24 by randomized study group;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in in SCr and estimated GFR from baseline to week 48.</measure>
    <time_frame>48 weeks</time_frame>
    <description>To assess renal glomerular safety by measuring change in SCr and estimated GFR from baseline to week 48 by randomized study group;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TRP, UGluc, URBP/UCr ratio, UB2MG, UProt/ UCr ratio from baseline to week 48</measure>
    <time_frame>48 weeks</time_frame>
    <description>To assess renal tubular function by measuring change in TRP, UGluc, URBP/UCr ratio, UB2MG, UProt/ UCr ratio by randomized study group;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 48 in glucose homeostasis (Fasting insulin)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 48 in glucose homeostasis (Fasting glucose)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 48 in glucose homeostasis (homeostasis model of insulin resistance (HOMA-IR)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare change in baseline to week 12 in 25-OHD serum concentrations by randomized study group</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare change in baseline to week 24 in 25-OHD serum concentrations by randomized study group</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare change in baseline to week 48 in 25-OHD serum concentrations by randomized study group.</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the LS mean 25-OHD serum concentration over the 48 week time period between the randomized study groups.</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BMD/BMC at Baseline</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in mean BMD/BMC between Baseline and Week 24</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in mean BMC/BMC between Baseline and Week 48</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Ca-PO4-FGF23 activity marker at Baseline</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in mean Ca-PO4-FGF23 activity marker between Baseline and Week 24</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in mean Ca-PO4-FGF23 activity marker between Baseline and Week 48</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean value of bone turnover marker at Baseline</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in mean value of bone turnover marker between Baseline and Week 24</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in mean value of bone turnover marker between Baseline and Week 48</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with renal glomerular and tubular toxicity at Baseline</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with renal glomerular and tubular toxicity at Week 24</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with renal glomerular and tubular toxicity at Week 48</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean glucose homeostasis (fasting insulin) at Baseline</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean glucose homeostasis (fasting insulin) between Baseline and Week 24</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean glucose homeostasis (fasting insulin) between Baseline and Week 48</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean glucose homeostasis (fasting glucose) at Baseline</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean glucose homeostasis (fasting glucose) between Baseline and Week 24</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean glucose homeostasis (fasting glucose) between Baseline and Week 48</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean glucose homeostasis (HOMA-IR) at Baseline</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean glucose homeostasis (HOMA-IR) between Baseline and Week 24</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean glucose homeostasis (HOMA-IR) between Baseline and Week 48</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">214</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Group A: Vitamin D3 50,000 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Vitamin D3 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3 50,000 IU</intervention_name>
    <description>Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
    <arm_group_label>Group A: Vitamin D3 50,000 IU</arm_group_label>
    <other_name>Vitamin D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3 placebo</intervention_name>
    <description>Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
    <arm_group_label>Group B: Vitamin D3 placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To be considered eligible for enrollment, an individual must meet the criteria listed below
        at the time of randomization:

        NOTE: If the DXA scan is scheduled prior to randomization, , all eligibility criteria must
        be met prior to performing the DXA scan.

          -  Age 16 years and 0 days to 24 years and 364 days;

          -  Behaviorally infected with HIV (e.g., sexual contact, injection drug use; not infected
             by perinatal transmission, blood transfusion, or at age younger than 9 years);

          -  HIV-1 infection as documented in subject's medical record by at least one of the
             following criteria:

               -  reactive HIV screening test result with an antibody based FDA-licensed assay
                  followed by a positive supplemental assay (e.g., HIV-1 Western Blot, HIV-1
                  Indirect Immunofluorescence, Antibody Differentiation Assay (Multispot)); or

               -  positive HIV-1 DNA PCR assay; or

               -  plasma HIV-1 quantitative RNA assay &gt;1,000 copies/mL; or

               -  positive plasma HIV-1 RNA qualitative assay

          -  Subjects must have at least one documented HIV viral load that is below 200 copies/mL
             collected following initiation of TDF containing cART and greater than 90 days prior
             to randomization; no HIV viral load above 200 copies/mL if measured within the 90 days
             prior to randomization; and an HIV viral load obtained at screening that is below 200
             copies/mL.

          -  Currently being treated for at least 180 days by the time of randomization with a TDF
             containing cART with at least 2 other FDA approved ARVs (NOTE: This may include a
             TDF-containing fixed drug combination medication);

          -  Negative serum hepatitis B surface antigen (HBsAg) at screening or by history within 4
             weeks prior to screening (see section 7.1.3);

          -  Willingness and ability to remain on the same cART regimen for the duration of study
             participation;

          -  Willingness and ability to participate in the study, follow all study procedures for
             the duration of study participation, and provide written informed consent or assent
             with parental permission, if applicable; and

          -  For females of child-bearing potential, agreement to use a minimum of one
             proven-effective method of birth control and willingness to postpone pregnancy for the
             duration of study participation (see section 5.3.2 for permitted hormonal
             contraceptives)

        Exclusion Criteria:

        To be considered eligible for enrollment, an individual must not meet any of the criteria
        listed below at the time of randomization:

        NOTE: If the DXA scan is scheduled prior to randomization, all eligibility criteria must be
        met prior to performing the DXA scan.

          -  Prior hypersensitivity to vitamin D;

          -  History of sarcoidosis, arteriosclerosis, renal stones, glomerulonephritis,
             interstitial kidney disease, nephrotic syndrome, hypercalcemia, osteoporosis and/or
             other bone diseases, clinical diagnosis of hypoparathyroidism or hyperparathyroidism;

          -  Lactation or pregnancy currently or within the past 24 weeks;

          -  Chemotherapy or radiation therapy for malignancy within the past 12 months;

          -  Known presence of GI disease that, in the opinion of the clinician, would interfere
             with study agent administration or absorption (e.g. Crohn's, Colitis);

          -  For subjects â‰¥ 18 years, confirmed creatinine clearance &lt; 70 ml/min (estimated GFR
             from SCr using CG equation) and for subjects &lt;18 years, confirmed creatinine clearance
             &lt; 70ml/min/1.73m2 (estimated GFR from SCr using Schwartz formula (see section 3.5).
             (Estimated GFR may be calculated using the formulae programmed on the ATN website;

          -  SCa &gt; Upper Limit Normal (ULN) for local laboratory values (see section 7.1.3);

          -  Active Grade 3 or higher clinical or laboratory toxicity except ATV associated
             indirect hyperbilirubinemia (see section 9.5.2.2);

          -  Weight is &gt; 350 pounds (lbs) or 159 kilograms (kgs);

          -  Positive hepatitis C antibody by history or at screening (see section 7.1.3); and

          -  Use of any medications as specified in sections 5.3.1, 5.3.3 and 5.4.

          -  Females Only: Use of certain hormonal contraceptives as specified in the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Havens, MD</last_name>
    <role>Study Chair</role>
    <affiliation>MACC Fund Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hopsital of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California - NICHD Westat Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Diagnostic and Treatment Center - NICHD Westat Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Jacksonville - NICHD Westat Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stroger Hospital and the CORE Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University - NICHD Westat Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fenway Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hopsital of Philadelphia - NICHD Westat Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Childrens Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan City Hospital (Puerto Rico) - NICHD Westat Site</name>
      <address>
        <city>San Juan</city>
        <zip>00936-5067</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.atnonline.org</url>
    <description>ATN website</description>
  </link>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2012</study_first_submitted>
  <study_first_submitted_qc>December 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2012</study_first_posted>
  <last_update_submitted>July 1, 2016</last_update_submitted>
  <last_update_submitted_qc>July 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 18, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

